Gritstone bio, Inc. (GRTS)

Market Cap	145.87M
Revenue (ttm)	10.23M
Net Income (ttm)	-138.96M
Shares Out	95.34M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,782,906
Open	1.32
Previous Close	1.30
Day's Range	1.28 - 1.55
52-Week Range	1.14 - 4.05
Beta	0.63
Analysts	Strong Buy
Price Target	7.33 (+379.09%)
Earnings Date	Nov 8, 2023

About GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 28, 2018
• Employees: 233
• Stock Exchange: NASDAQ
• Ticker Symbol: GRTS

Financial Performance

In 2022, Gritstone bio's revenue was $19.95 million, a decrease of -58.63% compared to the previous year's $48.21 million. Losses were -$119.69 million, 59.4% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for GRTS stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 379.09% from the latest price.

Price Target

$7.33

(379.09% upside)

Analyst Consensus: Strong Buy